Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy

Epilepsy and Behavior

Volumn 21, Issue 1, 2011, Pages 27-30

  Meng, Hongmei ^b   Guo, Guimei ^b   Ren, Jinyan ^b   Zhou, Hui ^a   Ge, Yubin ^a,c   Guo, Yingjie ^a  

^a JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carbamazepine; Epilepsy; Pharmacogenomics; Pharmacoresistance; Polymorphism

Indexed keywords

CARBAMAZEPINE;

ABCB1 GENE; ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; DNA SEQUENCE; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; GENE; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; COHORT STUDIES; DRUG RESISTANCE; EPILEPSY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 79955612469     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.02.015     Document Type: Article

References (32)

1. Sills G.J., Mohanraj R., Butler E., et al. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005, 46:643-647.
2. Löscher W., Klotz U., Zimprich F., Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009, 50:1-23.
3. Dombrowski S.M., Desai S.Y., Marroni M., et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001, 42:1501-1506.
4. Potschka H., Fedrowitz M., Löscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 2001, 12:3557-3560.
5. Potschka H., Fedrowitz M., Löscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain-barrier: evidence from microdialysis experiments in rats. Neurosci Lett 2002, 327:173-176.
6. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75:13-33.
7. Hoffmeyer S., Burk O., von Richter O., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
8. Wang D., Sadée W. Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J 2006, 8:515-520.
9. Zimprich F., Sunder-Plassmann R., Stogmann E., et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 2004, 63:1087-1089.
10. Luna-Tortós C., Fedrowitz M., Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology 2008, 55:1364-1375.
11. Seo T., Ishitsu T., Ueda N., et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics 2006, 7:551-561.
12. Ozgon G.O., Bebek N., Gul G., Cine N. Association of MDR1 (C3435T) polymorphism and resistance to carbamazepine in epileptic patients from Turkey. Eur Neurol 2008, 59:67-70.
13. Simon C., Stieger B., Kullak-Ublick G.A., et al. Intestinal expression and cytochrome P450 enzymes and ABC transporters and carbamazepine and phenytoin disposition. Acta Neurol Scand 2007, 115:232-242.
14. Gümüş-Akay G., Rüstemoǧlu A., Karadaǧ A., Sunguroǧlu A. Genotype and allele frequencies of MDR1 gene C1236T polymorphism in a Turkish population. Genet Mol Res 2008, 28:1193-1199.
15. Vahab S.A., Sen S., Ravindran N., et al. Analysis of genotype and haplotype effects of ABCB1 polymorphisms in the risk of medically refractory epilepsy in an Indian population. Drug Metab Pharmacokinet 2009, 24:255-260.
16. Nakamura T., Sakaeda T., Horinouchi M., et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 2002, 71:297-303.
17. Sakaeda T., Nakamura T., Horinouchi M., et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001, 18:1400-1404.
18. Siddiqui A., Kerb R., Weale M.E., et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003, 348:1442-1448.
19. Hung C.C. Jen Tai J, Kao PJ, Lin MS, Liou HH. Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 2007, 8:1151-1158.
20. Soranzo N., Cavalleri G.L., Weale M.E., et al. Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene. Genome Res 2004, 14:1333-1344.
21. Hung C.C., Tai J.J., Lin C.J., Lee M.J., Liou H.H. Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response. Pharmacogenomics 2005, 6:411-417.
22. Ebid A.H., Ahmed M.M., Mohammed S.A. Therapeutic drug monitoring and clinical outcomes in epileptic Egyptian patients: a gene polymorphism perspective study. Ther Drug Monit 2007, 29:305-312.
23. Kwan P., Baum L., Wong V., et al. Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav 2007, 11:112-117.
24. Tan N.C., Heron S.E., Scheffer I.E., et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 2004, 63:1090-1092.
25. Kim D.W., Kim M., Lee S.K., Kang R., Lee S.Y. Lack of association between C3435T nucleotide MDR1 genetic polymorphism and multidrug-resistant epilepsy. Seizure 2006, 15:344-347.
26. Kim Y.O., Kim M.K., Woo Y.J., et al. Single nucleotide polymorphism in the multidrug resistance 1 gene in Korean epileptics. Seizure 2006, 15:67-72.
27. Leschziner G., Jorgensen A.L., Andrew T., et al. Clinical factors and ABCB1 polymorphisms in prediction of antiepileptic drug response: a prospective cohort study. Lancet Neurol 2006, 5:668-676.
28. Shahwan A., Murphy K., Doherty C., et al. The controversial association of ABCB1 polymorphisms in refractory epilepsy: an analysis of multiple SNPs in an Irish population. Epilepsy Res 2007, 73:192-198.
29. Dericioglu N., Babaoglu M.O., Yasar U., Bal I.B., Bozkurt A., Saygi S. Multidrug resistance in patients undergoing resective epilepsy surgery is not associated with C3435T polymorphism in the ABCB1 gene. Epilepsy Res 2008, 1:42-46.
30. Lakhan R., Misra U.K., Kalita J., et al. No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy Behav 2009, 14:78-82.
31. Giessmann T., May K., Modess C., et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004, 76:192-200.
32. Kwan P., Arzimanoglou A., Berg A.T., et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.